Advertisement

Psychopharmacology

, Volume 120, Issue 4, pp 400–408 | Cite as

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

  • C. Smadja
  • R. Maldonado
  • S. Turcaud
  • M. C. Fournie-Zaluski
  • B. P. Roques
Original Investigation

Abstract

Systemic administration of RB 101, a complete inhibitor of the enkephalin degrading enzymes, has been reported to induce naltrindole-reversed anti-depressant-like effects in the conditioned suppression of motility (CSM) test in mice. The selective CCKB antagonist L-365,260 also elicits the same naltrindole-blocked responses on CSM. The aim of this study was therefore to investigate the possible modulation of RB 101 induced behavioral responses by activation or blockade of CCK receptors. Thus, the effects induced by RB 101 administered alone or associated with an ineffective dose of a selective CCKB agonist (BC 264), a CCKB antagonist (L-365,260) or a CCKA antagonist (L-364,718), were evaluated on the CSM in mice. RB 101 alone decreased the stress-induced loss of motility, as previously reported. The antidepressant-like effect of RB 101 was potentiated by L-365,260, and suppressed by BC 264 and to a lesser extent by L-364,718. The facilitatory effect induced by L-365,260 on RB 101 responses was blocked by the delta selective antagonist naltrindole. All these effects occurred only in shocked animals. The present results suggest that the activation of CCKA and CCKB receptors by endogenous CCK, could play an opposite role in the control of behavioral responses induced by endogenous enkephalins. Delta opioid receptors seem to be selectively involved in this interaction.

Key words

Conditioned suppression of motility Antidepressant-like effects Enkephalin-degrading enzymes RB 101 L-365,260 BC 264 L-364,718 δ-Opioid receptors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioidδ and dopamine D1 receptor stimulation. Eur J Pharmacol 216:157–166Google Scholar
  2. Barber NS, Dourish CT, Hill DR (1989) The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39:307–328Google Scholar
  3. Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, Cesselin F (1991) Differential inhibitory/stimulatory modulation of spinal CCK release byμ andδ opioid agonists, and selective blockade ofμ-dependent inhibition byκ receptor stimulation. Neurosci Lett 124:204–207Google Scholar
  4. Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, Cesselin F (1992) Opioid control of CCK-like material from the rat substantia nigra. J Neurochem 58:916–922Google Scholar
  5. Butcher SP, Varro A, Kelly JS, Dockray GJ (1989) In vivo studies on the enhancement of cholecystokinin release in the rat striatum. Brain Res 505:119–122Google Scholar
  6. Calenco-Choukroun G, Daugé V, Gacel G, Roques BP (1991) Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by aμ-opioid receptor agonist. Eur J Pharmacol 209:267–271Google Scholar
  7. Cesselin F, Bourgoin S, Artaud F, Hamon M (1984) Basic and regulatory mechanisms of in vitro release of Met-enkephalin from the dorsal zone of the rat spinal cord. J Neurochem 43:763–773Google Scholar
  8. Chang RLS, Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc Natl Acad Sci USA. 83:4923–4926Google Scholar
  9. Chang RLS, Lotti VJ, Chen TB, Kunkel KA (1986) Characterization of the binding of [3H]-(±)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212–217Google Scholar
  10. Charpentier B, Durieux C, Peleprat D, Dor A, Reibaud M, Blanchard JC, Roques BP (1988) Enzyme resistant CCK analogs with high affinities for central receptors. Peptides 9:835–841Google Scholar
  11. Cooper SJ (1991) Interactions between endogenous opioids and dopamine: implications for reward and aversion. In: Willner P, Scheel-Kruger (eds) The mesolimbic dopaminergic system: from motivation to action. John Wiley,Google Scholar
  12. Daugé V, Rossignol P, Roques BP (1988) Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective m and dopioid peptides or kelatorphan an inhibitor of enkephalin-degrading enzymes. Psychopharmacology 96:343–352Google Scholar
  13. De Felipe MC, Jiménez I, Castro A, Fuentes JA (1989) Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur J Pharmacol 159:175–180Google Scholar
  14. Derrien M, Noble F, Maldonado R, Roques BP (1993) CCK-A or CCK-B receptors activation lead to antinociception and to hyperalgesia respectively: evidence for an indirect interaction with the opioidergic system. Neurosci Lett 160:193–196Google Scholar
  15. Derrien M, Durieux C, Roques BP (1994) Antidepressant-like effects of CCK-B antagonists in mice: antagonism by Naltrindole. Br J Pharmacol 111:956–960Google Scholar
  16. Ding XZ, Bayer BM (1993) Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res 625:139–144Google Scholar
  17. Dockray GJ (1976) Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264:568–570Google Scholar
  18. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990) The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176:35–44Google Scholar
  19. Durieux C, Ruiz-Gayo M, Pelaprat D, Roques BP (1986) Investigation on the metabolism of CCK8 analogues by rat brain slices. Neuropeptides 7:1–9Google Scholar
  20. Durieux C, Ruiz-Gayo M, Couringer PJ, Bergeron F, Ducos B, Roques BP (1992) [3H]pBC 264, a suitable probe for studying cholecystokinin-β receptors binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol, 41:1089–1095Google Scholar
  21. Faris PL, Komisaruk B, Waitkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:1449–1451Google Scholar
  22. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP (1992) Mixed-inhibitor prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2474–2481Google Scholar
  23. Gall C, Lauterborn J, Burks D, Seroogy K (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 403:403–408Google Scholar
  24. Gaudreau P, Lavigne GJ, Quirion R (1990) Cholecystokinin antagonists proglumide, Lorglumide and benzotrip, but not L-365,718 interact with brain opioid binding sites. Neuropeptides 16:51–55Google Scholar
  25. Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide antagonists. J Neurosci 7:2967–2976Google Scholar
  26. Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476–478Google Scholar
  27. Innis RB, Snyder SH (1980) Distinc cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77:6917–6921Google Scholar
  28. Itoh S, Katsuura G, Maeda Y (1982) Caerulein and cholecystokinin suppressβ-endorphin-induced analgesia in the rat. Eur J Pharmacol 80:421–425Google Scholar
  29. Kameyama T, Nagasaka M (1982) Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. Pharmacol Biochem Behav 17:59–63Google Scholar
  30. Kameyama T, Nagasaka M, Yamada K (1985) Effects of antide-pressant drugs on a quickly learned conditioned suppression responses in mice. Neuropharmacology 24:59–63Google Scholar
  31. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF, Beinborn M (1992) Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 89:3605–3609Google Scholar
  32. Ladurelle N, Keller G, Roques BP, Daugé V (1993) Effects of CCK8 and of a CCKB-selective agonist BC264 on extracellular dopamine content in the posterieur nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628:254–262Google Scholar
  33. Lanaud P, Popovici T, Normand E, Lemoine C, Bloch B, Roques BP (1989) Distribution of CCK mRNA in particular regions (hippocampus, periaqueducal grey and thalamus) of the rat by in situ hybridization. Neurosci Lett 104:38–42Google Scholar
  34. Lavigne GJ, Millington WR, Mueller GP (1992) The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 21:119–129Google Scholar
  35. Maldonado R, Daugé V, Feger J, Roques BP (1990) Chronic blockade of D2 but not D1 dompamine receptors facilitates behavioural responses to endogenous enkephalins protected by kelatorphan administered in the accumbens in rats. Neuropharmacology 29:215–223Google Scholar
  36. Maldonado R, Derrien M, Noble F, Roques BP (1993) Association of the peptidase inhibitor and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 4:947–950Google Scholar
  37. Moran TH, Robilson MS, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors for behavioural actions. Brain Res 362:175–179Google Scholar
  38. Nabeshima T, Katoh A, Kameyama T (1988) Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility. J Pharmacol Exp Ther 244:303–309Google Scholar
  39. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Inhibition of the enkephalinmetabolizing enzymes by the first systematically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261:181–190Google Scholar
  40. Noble F, Derrien M, Roques BP (1993) Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109:1064–1070Google Scholar
  41. Noble F, Smadja C, Roques BP (1994) Role of endogenous cholecystokinin in the facilitation ofμ-mediated antinociception byδ-agonist. J Pharmacol Exp Ther 271:1127–1134Google Scholar
  42. Pélaprat D, Broer Y, Studler JM, Peschanski M, Tassin JP, Glowinski J, Rostène W, Roques BP (1987) Autoradiography of CCK receptors in the rat brain using [3H]Boc[Nle28,31] CCK27–33 and [125I] Bolton-Hunter CCK8. Functional significance of subregional distributions. Neurochem Int 10:495–508Google Scholar
  43. Pohl M, Benoliel JJ, Bourgoin S, Lombard MC, Mauborgne A, Taquet H, Carayon A, Besson JM, Cesselin F, Hamon M (1990) Regional distribution of calcitonin gene-related peptide-, substance P, cholecystokinin-, Met-enkephalin-, and dynorphin A (1–8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55:1122–1130Google Scholar
  44. Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptideδ-opioid receptor antagonist. Eur J Pharmacol 146:185–186Google Scholar
  45. Roques BP, Daugé V, Gacel G, Fournié-Zaluski MC (1985) Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalin metabolism. Potential use in treatment of mental illness. In Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry developments in psychiatry, vol 7. Elsevier, pp 287–289Google Scholar
  46. Ruiz-Gayo M, Durieux C, Fournié-Zaluski MC, Roques BP (1992) Stimulation of ∂-opioid receptors binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59:1805–1811Google Scholar
  47. Saito A, Sankaran H, Goldfine ID, Williams JA (1980) Cholecystokinin receptors in the brain: characterization and distribution. Science 208:1155–1156Google Scholar
  48. Sakamoto C, Williams JA, Godfine ID (1984) Brain CCK receptors are structurally distinct from pancreas CCK receptors. Biochem Biophys Res Commun 124:497–502Google Scholar
  49. Tejedor-Real P, Micó JA, Maldonado R, Roques BP, Gibert-Rahola J (1993) Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalins degrading enzymes on a model of depression in the rat. Biol Psychiatry 34:100–107Google Scholar
  50. Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP (1994) CCK-B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270:77–88Google Scholar
  51. Wang XJ, Hans JS (1990) Modification by cholecystokinin octapeptide of the binding ofμ-δ- andκ-opioid receptors. J Neurochem 55:1379–1382Google Scholar
  52. Wank SA, Pisegna JR, Weerth A (1992) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 89:8691–8695Google Scholar
  53. Watkins LR, Kinscheck IB, Mayer DJ (1985) Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 327:169–180Google Scholar
  54. Wiesenfeld-Hallin Z, Xu XH, Hughes J, Horwell DC, Hökfelt T (1990) PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 87:7105–7109Google Scholar
  55. Willner P (1990) Animal models of depression: an overview. Pharmacol Ther 45:425–455Google Scholar
  56. Wise RA (1983) Brain neuronal systems mediating reward processes. In: Smith JE, Lane JD (eds) Neurobiologie of opiate reward processes. Elsevier/North Holland Biomedical Press, Amsterdam, pp 405–437Google Scholar
  57. Zimmerman M (1983) Guest editorial. Pain 16:109–110Google Scholar
  58. Zhou Y, Sun YH, Zhang ZW, Han JS (1992) Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. Neuroreport 3:1121–1123Google Scholar
  59. Zuzel K, Rose C, Schwartz JC (1985) Assessment of the role of “enkephalinase” in cholecystokinin inactivation. Neuroscience 15:149–158Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • C. Smadja
    • 1
  • R. Maldonado
    • 1
  • S. Turcaud
    • 1
  • M. C. Fournie-Zaluski
    • 1
  • B. P. Roques
    • 1
  1. 1.Département de Pharmacochimie Moléculaire et StructuraleINSERM U266, CNRS URA D 1500, UFR des Sciences Pharmaceutiques et BiologiquesParis Cedex 06France

Personalised recommendations